Clinical trials: Neuroblastoma (NB)
Recurrent Neuroblastoma
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma
Neuroblastoma is the second most frequent cause for death from cancer in childhood. Already one year after diagnosis of recurrence from high risk neuroblastoma, 75% of the patients experience further progression.
- Trial name
- METRO-NB2012 (NCT02641314)
- Testing
- metronomic therapy
- Where
- 8 sites in Germany
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Neuroblastoma (NB), Prognosis
Risk Model for Metastasis Detection of Neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting for about 15% of tumor-related mortality.
- Conditions
- Neuroblastoma (NB), Prognosis, Bone Marrow Metastasis, Bone Metastases
- Trial name
- NB (NCT06703944)
- Testing
- risk model in diagnosis and prognosis
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Neuroblastoma, High-risk Neuroblastoma
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
- Conditions
- Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
- Trial name
- NCT06057948
- Testing
- OPT-821 (QS-21), oral β-glucan
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma, Neuroblastoma (NB)
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment
- Conditions
- Neuroblastoma, Neuroblastoma (NB), Neuroblastoma (NBL), Neuroblastoma (Measurable Disease)
- Trial name
- NCT07223606
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Sponsor
- ProgenaBiome
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.
- Trial name
- NCT02748135
- Testing
- TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg
- Where
- 10 sites in United States
- Volunteers
- 18 people
- Sponsor
- Oncurious NV
Neuroblastoma (NB)
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
- Trial name
- NCT07767630
- Testing
- [211At]MABG
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Neuroblastoma (NB), Neuroblastoma in Children
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma.
- Trial name
- NCT07318831
- Testing
- Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neuroblastoma
A Pilot Study on ALK Gene Mutations in Neuroblastoma
Neuroblastoma (NB) originates from the sympathetic nervous system and is one of the most common cancers in infants and children.
- Trial name
- NCT01986595
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Neuroblastoma (NB), Ganglioneuroblastoma
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB) is a malignant neoplasm of the sympathetic nervous system, occurring in 1 in 8,000 live births, accounting for 6-10% of all childhood malignant neoplasms and responsible for 12-15% of mortality -, making it the…
- Trial name
- NB-NK-2026 (NCT07375563)
- Testing
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cell, irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Where
- Russia
- Volunteers
- 5 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Neuroblastoma (NB), Desmoplastic Small Round Cell Tumor (DSRCT)
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Title: Safety and efficacy of CAR-T cell therapy for relapsed/refractory neuroblastoma and desmoplastic small round cell tumors: a single-arm, open-label trial.
- Trial name
- NCT06836505
- Testing
- CART therapy
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
Neuroblastoma, Pediatric Cancer
A Study of N9 Chemotherapy in Children With Neuroblastoma
The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times …
- Trial name
- NCT04947501
- Testing
- Cyclophosphamide, Topotecan, Vincristine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma (NB)
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF.
- Trial name
- NCT03189706
- Testing
- Irinotecan, temozolomide, Hu3F8
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma (NB)
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
The goal of this prospective observational study is to evaluate the diagnostic performance of ¹²³I-MIBG SPECT/CT and SSTR PET in Chinese children with suspected or confirmed neuroblastoma (NB).
- Trial name
- MIBG & SSTR NB (NCT07064746)
- Testing
- ¹²³I-MIBG SPECT/CT, SSTR PET
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University